Holen Sie sich die Stockscreener-App
0.60
4.17%
0.024
Vorhandelsmarkt:
.63
0.03
+5.00%
Schlusskurs vom Vortag:
$0.576
Offen:
$0.59
24-Stunden-Volumen:
970.79K
Relative Volume:
1.20
Marktkapitalisierung:
$23.77M
Einnahmen:
$1.04M
Nettoeinkommen (Verlust:
$-67.50M
KGV:
-0.3121
EPS:
-1.9222
Netto-Cashflow:
$-60.67M
1W Leistung:
+11.98%
1M Leistung:
-1.20%
6M Leistung:
-85.04%
1J Leistung:
-73.09%
1-Tages-Spanne:
$0.586
$0.615
1-Wochen-Bereich:
$0.521
$0.6298
52-Wochen-Spanne:
$0.43
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Firmenname
Vistagen Therapeutics Inc
Sektor
Branche
Telefon
650-577-3600
Adresse
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.60 | 22.20M | 1.04M | -67.50M | -60.67M | -1.9222 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-17 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-17 | Herabstufung | Maxim Group | Buy → Hold |
| 2025-12-17 | Herabstufung | Stifel | Buy → Hold |
| 2025-12-17 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-12-07 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-07 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-07-22 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-02-18 | Eingeleitet | Jefferies | Buy |
| 2021-01-04 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | Eingeleitet | Maxim Group | Buy |
| 2018-02-08 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-03-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Vistagen Therapeutics Inc Aktie (VTGN) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Connect - ACCESS Newswire
Vistagen Therapeutics, Inc. Files Form 8-K with SEC – Company Information, Address, and Stock Details (April 2026) - Minichart
Vistagen Therapeutics grants stock options to executives and employees - Investing.com
VistaGen Therapeutics Grants Broad Employee Retention Stock Options - TipRanks
Vistagen awards stock options to CEO Shawn K. Singh and CFO Nick B. Tressler - TradingView — Track All Markets
[8-K] Vistagen Therapeutics, Inc. Reports Material Event - Stock Titan
Institution Moves: Will Vistagen Therapeutics Inc outperform during market ralliesPortfolio Growth Summary & AI Forecasted Entry and Exit Points - baoquankhu1.vn
2026-04-12 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Reach Out | NDAQ:VTGN | Press Release - Stockhouse
Trading Recap: What is the next catalyst for Vistagen Therapeutics IncInsider Selling & Low Volatility Stock Suggestions - baoquankhu1.vn
Vistagen Therapeutics Inc (MEX:VTGN) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Is Vistagen Therapeutics Inc a potential multi bagger2026 Reactions & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Hedge Fund Bets: Can Vistagen Therapeutics Inc sustain earnings growthMarket Volume Summary & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Quarterly Risk: Can Vistagen Therapeutics Inc sustain earnings growth2026 Growth vs Value & Weekly Momentum Picks - baoquankhu1.vn
Vistagen Therapeutics Inc (MEX:VTGN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Vistagen (VTGN) CFO awarded 75,000 stock options at $0.5358 - Stock Titan
Vistagen (NASDAQ: VTGN) CEO receives 75K stock options grant - Stock Titan
Vistagen (VTGN) awards stock options to its Chief Legal Officer - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bull Run: Should value investors consider Vistagen Therapeutics Inc2026 Breakouts & Daily Profit Focused Stock Screening - baoquankhu1.vn
RSI Check: Why is Vistagen Therapeutics Inc stock going downBull Run & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Vistagen Therapeutics, Inc. (VTGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
VistaGen Faces Nasdaq Audit Committee Compliance Setback - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Connect - ACCESS Newswire
Vistagen Therapeutics notifies Nasdaq of audit committee non-compliance By Investing.com - Investing.com Canada
Vistagen Therapeutics notifies Nasdaq of audit committee non-compliance - investing.com
Vistagen Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Risk Report: Will Vistagen Therapeutics Inc outperform during market ralliesPortfolio Gains Report & Weekly High Return Stock Opportunities - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
2026-03-31 | Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Stockholders to Inquire about Securities Investigation | NDAQ:VTGN | Press Release - Stockhouse
Pullback Watch: What is the next catalyst for Vistagen Therapeutics IncShort Setup & Weekly Top Performers Watchlists - baoquankhu1.vn
Vistagen Therapeutics Inc Stock Operating Data - GuruFocus
Geopolitics Watch: Will Vistagen Therapeutics Inc. outperform during market rallies2026 Opening Moves & Community Verified Trade Alerts - baoquankhu1.vn
Biopharma's Brass Hid Anxiety Drug Trial Risks, Investor Says - Law360
Vistagen Therapeutics Inc Stock Baskets - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Reach Out - ACCESS Newswire
Vistagen Therapeutics (MEX:VTGN) Dividends Paid - GuruFocus
Layoff Tracker: Takeda Restructuring Will Affect Workforce, Could Include Layoffs - biospace.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Stockholders to Connect - ACCESS Newswire
If You Invested $1,000 in Vistagen Therapeutics Inc (VTGN) - Stock Titan
Momentum Shift: What is the implied volatility of Vistagen Therapeutics Inc2026 Technicals & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Vistagen Therapeutics, Inc. (VTGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Vistagen Therapeutics, Inc. Announces Resignation of Mary Rotunno as Director, Effective April 1, 2026 - marketscreener.com
Vistagen (NASDAQ: VTGN) director Mary Rotunno resigns from board effective April 1, 2026 - Stock Titan
VistaGen Showcases Intranasal Pherine Pipeline in New Presentation - The Globe and Mail
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN - ChartMill
FinancialContentINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN - FinancialContent
VistaGen at Stifel CNS Forum: Strategic Insights on Fasedienol By Investing.com - Investing.com Canada
Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN)March 16, 2026 Deadline to JoinContact Levi & Korsinsky - PR Newswire
Vistagen (NASDAQ: VTGN) details pherine CNS pipeline in new presentation - Stock Titan
Finanzdaten der Vistagen Therapeutics Inc-Aktie (VTGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):